# A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

> **NCT02289703** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 16 (actual)

## Conditions studied

- End-Stage Renal Disease

## Interventions

- **DRUG:** Rivaroxaban 15 mg

## Key facts

- **NCT ID:** NCT02289703
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289703, "A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02289703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*